- Home
- PBFS vs NMRA Comparison
PBFS vs NMRA Comparison
Compare PBFS & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBFS
- NMRA
- Stock Information
- Founded
- PBFS 1889
- NMRA 2019
- Country
- PBFS United States
- NMRA United States
- Employees
- PBFS N/A
- NMRA N/A
- Industry
- PBFS Banks
- NMRA
- Sector
- PBFS Finance
- NMRA
- Exchange
- PBFS Nasdaq
- NMRA Nasdaq
- Market Cap
- PBFS 278.5M
- NMRA 287.6M
- IPO Year
- PBFS N/A
- NMRA 2023
- Fundamental
- Price
- PBFS $11.26
- NMRA $0.65
- Analyst Decision
- PBFS
- NMRA Buy
- Analyst Count
- PBFS 0
- NMRA 8
- Target Price
- PBFS N/A
- NMRA $9.29
- AVG Volume (30 Days)
- PBFS 16.3K
- NMRA 1.2M
- Earning Date
- PBFS 05-12-2025
- NMRA 05-06-2025
- Dividend Yield
- PBFS N/A
- NMRA N/A
- EPS Growth
- PBFS 11.77
- NMRA N/A
- EPS
- PBFS 0.76
- NMRA N/A
- Revenue
- PBFS $88,118,000.00
- NMRA N/A
- Revenue This Year
- PBFS N/A
- NMRA N/A
- Revenue Next Year
- PBFS N/A
- NMRA N/A
- P/E Ratio
- PBFS $14.82
- NMRA N/A
- Revenue Growth
- PBFS 21.67
- NMRA N/A
- 52 Week Low
- PBFS $8.76
- NMRA $0.62
- 52 Week High
- PBFS $12.20
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- PBFS 44.04
- NMRA 22.34
- Support Level
- PBFS $10.60
- NMRA $0.64
- Resistance Level
- PBFS $11.46
- NMRA $0.83
- Average True Range (ATR)
- PBFS 0.43
- NMRA 0.09
- MACD
- PBFS -0.01
- NMRA 0.02
- Stochastic Oscillator
- PBFS 49.08
- NMRA 6.68
About PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.